Company news
Corbus Pharmaceuticals Holdings, Inc. news in 2021
Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2021, newest first.
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
December 6, 2021
Corbus Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
November 11, 2021
Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
August 11, 2021
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
June 23, 2021
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
May 31, 2021
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
May 24, 2021
Corbus Pharmaceuticals announces adjournment of annual meeting
May 18, 2021
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
May 12, 2021
Corbus Pharmaceuticals Announces Completion of Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus (SLE)
April 19, 2021
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
March 29, 2021
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results
March 14, 2021
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2020 Results on March 15, 2021
March 7, 2021
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
January 19, 2021
Decks in 2021
- Investor Presentation (July 2021)
Investor deck · 54 slides · Jul 22, 2021
- Investor Presentation (June 2021)
Investor deck · 46 slides · Jun 1, 2021
- Conference Presentation (January 2021)
Conference · 26 slides · Jan 27, 2021